Navigation Links
Gene Network Sciences Announces Drug Development Collaboration with Biogen Idec
Date:10/1/2008

CAMBRIDGE, Mass., Oct. 1 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has entered into an agreement with Biogen Idec under which GNS will use its proprietary REFS(TM) software platform to process clinical data provided by Biogen Idec to identify targets and biomarkers in inflammation. A forward simulation model generated directly from the Biogen Idec data will be licensed to Biogen Idec at the conclusion of this project. Financial terms of the agreement were not disclosed.

GNS employs massively parallel supercomputers to probe vast amounts of raw human biological data to discover new insights into the biological causes of human disease, and new opportunities for diagnosis and treatment. Under this agreement, GNS will use its REFS(TM) (Reverse Engineering/Forward Simulation) platform to transform genetic, genomic, and clinical data provided by Biogen Idec to generate and score billions of hypotheses to discover new drug targets and biomarkers rapidly.

"Our proprietary technology is capable of taking raw 'omic' data and running billions of calculations in a short period of time to find potential biomarkers and promising drug targets that could lead to more effective patient treatments," said Colin Hill, CEO of GNS. "It is the value and speed of our REFS(TM) technology and the potential it offers to the Biogen Idec drug development program that forged our partnership."

About REFS(TM)

Reverse Engineering/Forward Simulation (REFS(TM)) is a technology that systematically turns multiple layers of biologically relevant data into an unprecedented view of human biology and disease as a "whole." REFS(TM) begins with raw biological data (genetic, genomic, epigenetic, proteomic, metabolomic and environmental) and rapidly performs billions upon billions of calculations to determine how the molecules interact with one another in the complete system (Reverse Engineering). These computer-assembled models are then queried rapidly through billions of in silico experiments (Forward Simulation) to discover the highest-impact molecular targets for the disease being studied and the corresponding efficacy and toxicity markers related to specific drug treatments. These findings are then tested in both the laboratory and the clinic, enabling a faster, more focused and more effective drug discovery and development process.

About Gene Network Sciences

Founded in 2000, Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data without any a priori knowledge. Headquartered in Cambridge, Massachusetts, GNS uses its REFS(TM) (reverse engineering and forward simulation) technology in pharmaceutical and clinical settings to rapidly turn complex and heterogeneous data sets into cell and organ-level computer models of disease biology, drug efficacy and drug safety. These models simulate mechanisms of disease and the clinical performance of drug candidates. By discovering how and why specific drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.

For more Information, please contact:

Lynn Blenkhorn Thomas Neyarapally

Feinstein Kean Healthcare Gene Network Sciences, Inc.

508-851-0930 617-494-0492

Lynn.blenkhorn@fkhealth.com tneyarapally@gnsbiotech.com


'/>"/>
SOURCE Gene Network Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Access Innovations Provides Support Services for Agis Network
2. Womens World Banking Welcomes New Network Member From Tunisia
3. Internet TV Network for Personal Trainers is Launched
4. Quality Innovators to Network in Atlanta Sept. 19-21: Learn from Those Who Got It Right
5. Guardians Dental Network Experiences Double-Digit Growth
6. Chronic infection persists by targeting stromal cell network in lymphoid organs
7. The American Pain Foundation (APF) and The HealthCentral Network Collaborate to Develop Enhanced Internet Resources for People with Pain
8. Blue Care Network of Michigan Earns National Leadership Award for Chronic Disease Management
9. AT&T Offers Network Industry-First RFID Solution for Health Care Organizations
10. AT&T Establishes New Network Services for Leading Medical Liability Insurer
11. Portico Systems to Share Provider Network Management Best Practices at Institute for International Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 2017 , ... Children and adolescents who enter the foster ... in the general population. That’s because foster care is designed to protect children ... no fault of their own, youth who have experienced trauma often have difficulty ...
(Date:4/28/2017)... ... , ... Bill Howe started his sewer and drain company in 1980 focusing ... the team, the Bill Howe brand was born and they began cultivating their mission ... to the San Diego community in which they worked, lived and were raising their ...
(Date:4/28/2017)... York (PRWEB) , ... April 28, 2017 , ... ... anti-aging skincare and advanced nutraceutical supplements, through its Nova Skin Sciences division, ... the hydrating benefits of a moisturizer with the power of an anti-aging concentrate. ...
(Date:4/27/2017)... ... April 27, 2017 , ... Today, Jefferson Health in Philadelphia ... announced an agreement to create the Jane and Leonard Korman Respiratory Institute in ... Leonard Korman Family Foundation. The collaboration leverages the strengths of each organization and ...
(Date:4/27/2017)... ... April 27, 2017 , ... Last night, Christine Collins of ... Year for her extraordinary compassion and lifelong dedication to serve others. Since 1997, ... for the prestigious award each year – identifying a CAREGiver who has exemplified ...
Breaking Medicine News(10 mins):
(Date:4/26/2017)... NEW PROVIDENCE, N.J. , April 26, 2017 ... to announce its fifteenth year of fulfilling its mission of ... pharmaceutical industry is highly scrutinized, Phoenix,s ... informing the healthcare community about the latest advances in science ... Phoenix was founded in 2002 by ...
(Date:4/21/2017)... 21, 2017 Halo Labs announces the launch ... analysis system called the Horizon at PEGS 2017 in ... new system analyzes sub visible particulate matter in biopharmaceutical ... screening as early as candidate selection and pre-formulation. ... contract research organization Elion Labs for system ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
Breaking Medicine Technology: